Production (Stage)
Inhibitor Therapeutics, Inc.
INTI
$0.054
$0.0048.00%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 4.32M | 5.61M | 6.38M | 7.10M | 7.68M |
| Total Receivables | -- | -- | -- | -- | -- |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 99.10K | 87.80K | 73.10K | 74.60K | 112.40K |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 4.42M | 5.69M | 6.45M | 7.17M | 7.79M |
|
|
|||||
| Total Current Assets | 4.42M | 5.69M | 6.45M | 7.17M | 7.79M |
| Net Property, Plant & Equipment | 84.30K | -- | -- | -- | -- |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | -- | -- | -- | -- | -- |
| Total Assets | 4.51M | 5.69M | 6.45M | 7.17M | 7.79M |
|
|
|||||
| Total Accounts Payable | 36.70K | 15.90K | 1.70K | 18.80K | 111.90K |
| Total Accrued Expenses | 32.00K | 693.70K | 42.90K | 16.70K | 43.90K |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 26.00K | -- | -- | -- | -- |
| Total Finance Division Other Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Current Liabilities | -- | -- | -- | -- | -- |
| Total Current Liabilities | 94.70K | 709.60K | 44.60K | 35.50K | 155.90K |
|
|
|||||
| Total Current Liabilities | 94.70K | 709.60K | 44.60K | 35.50K | 155.90K |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 58.40K | -- | -- | -- | -- |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 3.00M | 3.00M | 3.00M | 3.00M | 3.00M |
| Total Liabilities | 3.15M | 3.71M | 3.04M | 3.04M | 3.16M |
|
|
|||||
| Common Stock & APIC | 54.10M | 54.10M | 54.10M | 54.10M | 54.10M |
| Retained Earnings | -52.75M | -52.12M | -50.70M | -49.97M | -49.46M |
| Treasury Stock & Other | -- | -- | -- | -- | -- |
| Total Common Equity | 1.35M | 1.99M | 3.41M | 4.14M | 4.64M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 1.35M | 1.99M | 3.41M | 4.14M | 4.64M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 1.35M | 1.99M | 3.41M | 4.14M | 4.64M |
|
|
|||||